The successful management of SJS/TEN secondary to enfortumab vedotin therapy

The successful management of SJS/TEN secondary to enfortumab vedotin therapy

A 47-year-old female with poorly differentiated carcinoma of urothelial origin on pembrolizumab, presented to the hospital with fever, dysuria, pruritus, diffuse erythema, and skin desquamation 11 days after starting immunotherapy with enfortumab vedotin (EV). The desquamation covered about 25% of h...

Full description

Bibliographic Details
Main Authors: Rhea Singh, BS, Fnu Nutan, MD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Current Problems in Cancer: Case Reports
Subjects:
SJS
TEN
Enfortumab vedotin
Etanercept
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000266

Similar Items

Similar Items